New combo therapy aims to improve diabetes management
NCT ID NCT07580638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at adding a drug called Chiglitazar to standard SGLT-2 inhibitor treatment for adults with type 2 diabetes whose blood sugar is not well controlled. Researchers will track changes in blood sugar, heart, kidney, and liver health over time. About 3550 participants will receive their usual care, and data will be collected from routine check-ups. The goal is to see if this combination is more effective and safe for managing diabetes long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.